Clinical Trial

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Study acronym: SHOT
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-01-15; most recent amendment 2024-11-09.
Status change: Recruiting → Active, Not Recruiting 2024-11-09
Status change: Active, Not Recruiting → Recruiting 2017-01-24
Trial Details
NCT Number NCT03024684
Lead Sponsor Chiayi Christian Hospital
Collaborators: E-DA Hospital, National Taiwan University Hospital, Taichung Veterans General Hospital, Mackay Memorial Hospital, Tainan Municipal Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital
Conditions HepatoCellular Carcinoma
Enrollment 240 participants
Start Date 2017-01-03
Primary Completion 2025-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-12